Entrada Therapeutics (TRDA) Treasury Shares (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Treasury Shares of $2.8 million for Q1 2026, up 3.35% year-over-year from $2.7 million in Q1 2025, and up 535.59% quarter-over-quarter from $438500.0 in Q4 2025.
Entrada Therapeutics (TRDA) Treasury Shares (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Treasury Shares history runs 7 years deep, the most recent figure standing at $2.8 million for Q1 2026.
- In Q1 2026, Treasury Shares rose 3.35% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (up 3.35% YoY), while the FY2025 annual figure was $438500.0, down 77.72% from the prior year.
- Treasury Shares for Q1 2026 stood at $2.8 million, up from $438500.0 in the prior quarter.
- The five-year high for Treasury Shares was $2.8 million in Q1 2026, with the low at $438500.0 in Q3 2024.
- The 5-year median for Treasury Shares is $1.2 million (2023), against an average of $1.3 million.
- The sharpest annual moves came in 2022 and 2024: Treasury Shares plunged 99.68% in 2022, then soared 198.8% in 2024.
- Entrada Therapeutics' Treasury Shares stood at $463964.0 in 2022, then jumped by 173.4% to $1.3 million in 2023, then surged by 55.18% to $2.0 million in 2024, then plunged by 77.72% to $438500.0 in 2025, then jumped by 535.59% to $2.8 million in 2026.
- Business Quant data shows TRDA's Treasury Shares at $2.8 million in Q1 2026, $438500.0 in Q4 2025, and $438500.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | 2.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.88 Mn |
| Jun 30, 2026 | 2.88 Mn |
| Mar 31, 2026 | 2.79 Mn |
| Mar 31, 2026 | 2.79 Mn |
| Dec 31, 2025 | 438,500.00 |
| Dec 31, 2025 | 438,500.00 |
| Sep 30, 2025 | 438,500.00 |
| Sep 30, 2025 | 438,500.00 |
| Jun 30, 2025 | 2.48 Mn |
| Jun 30, 2025 | 2.48 Mn |
| Mar 31, 2025 | 2.70 Mn |
| Mar 31, 2025 | 2.70 Mn |
| Dec 31, 2024 | 1.97 Mn |
| Dec 31, 2024 | 1.97 Mn |
| Sep 30, 2024 | 438,500.00 |
| Sep 30, 2024 | 438,500.00 |
| Jun 30, 2024 | 2.01 Mn |
| Jun 30, 2024 | 2.01 Mn |
| Mar 31, 2024 | 2.01 Mn |
| Mar 31, 2024 | 2.01 Mn |